Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Non-Current Deffered Revenue (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $501000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 89.47% to $501000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $501000.0, a 89.47% decrease, with the full-year FY2024 number at $1.2 million, down 77.84% from a year prior.
  • Non-Current Deffered Revenue was $501000.0 for Q1 2025 at TScan Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $7.8 million in Q3 2023 to a low of $501000.0 in Q1 2025.
  • A 4-year average of $4.0 million and a median of $4.0 million in 2024 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: plummeted 48.26% in 2024, then crashed 89.47% in 2025.
  • TScan Therapeutics' Non-Current Deffered Revenue stood at $1.5 million in 2021, then skyrocketed by 275.55% to $5.6 million in 2023, then crashed by 77.84% to $1.2 million in 2024, then plummeted by 59.79% to $501000.0 in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Non-Current Deffered Revenue are $501000.0 (Q1 2025), $1.2 million (Q4 2024), and $3.7 million (Q3 2024).